The development of poly (ADP-ribose) polymerase inhibitors (PARPi) represents a novel approach to cancer treatment, targeting PARP1, PARP2, and PARP3 proteins crucial in repairing single-strand DNA breaks. This evidence concerns the gene PARP2 and cancer.